Vinca alkaloids and taxanes represent the mainstay of medical treatment of hematological and solid tumors. Unfortunately, a major clinical problem with these agents is drug resistance. Although a plethora of mechanisms of drug resistance have been described, only a few of them have been validated in clinical trials. Among these, the one involving the protein TUBB3 seems to represent a promising target for studying drug resistance. In fact, it seems that this protein is a factor promoting cell survival and represents an endogenous element of an inherent drug-resistance program built into cells to counteract the activity of microtubule-interacting drugs. Its pivotal role has been ascertained in clinical trials in lung, breast, and ovarian cancer, three diseases that can be successfully treated with microtubule-interacting drugs. Although TUBB3 is probably not a unique factor in drug resistance, the hope is that direct targeting of this protein will increase the response to microtubule-interacting drugs, thereby overcoming an important element in the growth of drug resistance. Â© 2007 Bentham Science Publishers Ltd.
|Digital Object Identifier (DOI):||10.2174/156800907783220453|
|Codice identificativo ISI:||WOS:000253935900003|
|Codice identificativo Scopus:||2-s2.0-37449017239|
|Titolo:||Looking at drug resistance mechanisms for microtubule interacting drugs: Does TUBB3 work?|
|Appare nelle tipologie:||1.1 Articolo in rivista|